The economic burden of drug resistance

Clinical Infectious Diseases

Volumn 41, Issue 4 SUPPL., 2005, Pages

  Howard, David H ^a,c   Scott II, R Douglas ^b  

^a EMORY UNIVERSITY   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; ANTIVIRUS AGENT; ARTEMISININ; CHLOROQUINE; QUININE; VANCOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; COST BENEFIT ANALYSIS; DRUG COST; ECONOMIC ASPECT; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFECTION CONTROL; MALARIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; OTITIS MEDIA; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; VANCOMYCIN RESISTANT ENTEROCOCCUS;

COMMUNICABLE DISEASES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG RESISTANCE; HEALTH CARE COSTS; HUMANS; INFECTION CONTROL; WORLD HEALTH;

EID: 23244445171     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/430792     Document Type: Review

References (17)

1. Elbasha EH. Deadweight loss of bacterial resistance due to over treatment. Health Econ 2003; 12:125-38.
2. Howard DH. Resistance-induced antibiotic substitution. Health Econ 2004; 13:585-95.
3. Puzniak LA, Gillespie KN, Leet T, Kollef M, Mundy LM. A cost-benefit analysis of gown use in controlling vancomycin-resistant Enterococcus transmission: is it worth the price? Infect Control Hosp Epidemiol 2004; 25:418-24.
4. Paladino JA, Sunderlin JL, Price CS, Schentag JJ. Economic consequences of antimicrobial resistance. Surg Infect (Larchmt) 2002; 3: 259-67.
5. Kaye KS, Engemann JJ, Mozaffari E, Carmeli Y. Reference group choice and antibiotic resistance outcomes. Emerg Infect Dis 2004; 10:1125-8.
6. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MR, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36:53-9.
7. Howard DH, Cordell R, McGowan J Jr, Packard R, Scott D, Solomon S. Measuring the economic costs of antimicrobial resistance in healthcare settings. Clin Infect Dis 2001; 33:1573-8.
8. Blot S, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002; 162:2229-35.
9. Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002; 162:2223-8.
10. Wisniewski MF, Kieszkowski P, Zagorski BM, Trick WE, Sommers M, Weinstein RA. Development of a clinical data warehouse for hospital infection control. J Am Med Inform Assoc 2003; 10:454-62.
11. Goodman CA, Coleman PG, Mills AJ. Changing the first line drug for malaria treatment-cost-effectiveness analysis with highly uncertain inter-temporal trade-offs. Health Econ 2001; 10:731-49.
12. Phillips M, Phillips-Howard PA. Economic implications of resistance to antimalarial drugs. Pharmacoeconomics 1996; 10:225-38.
13. Arrow KJ, Panosian CB, Gelband H, eds. Savings lives, buying time: economics of malaria drugs in an age of resistance. Washington, DC: National Academies Press, 2004.
14. Panosian CB. Economic access to effective drugs for falciparum malaria. Clin Infect Dis 2005; 40:713-7.
15. Metlay JP, Hofmann J, Cetron MS, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000;30:520-8.
16. Howard DH, McGowan J Jr. Initial and follow-up costs by treatment outcome for children with respiratory infections. Pediatrics 2004; 113: 1352-6.
17. Singer ME, Harding I, Jacobs MR, Jaffe DH. Impact of antimicrobial resistance on health outcomes in the outpatient treatment of adult community-acquired pneumonia: a probability model. J Antimicrob Chemother 2003; 51:1269-82.